Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,591.90
(
0.54%
)
US TECH 100
23,462.40
(
0.44%
)
Dow Jones
46,429.49
(
0.66%
)
Brent Oil
99.15
(
0.38%
)
Bitcoin
70,315.94
(
-1.39%
)
News Focus
News Focus
Post# of 30495
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122810
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: semi_infinite post# 21713

Tuesday, 04/14/2020 12:53:21 PM

Tuesday, April 14, 2020 12:53:21 PM

Post# of 30495
JNJ sees 2020 hit to med-device segment—but little if any adverse impact on the pharma and consumer-health segments:

https://finance.yahoo.com/news/johnson-johnson-reports-2020-first-103100583.html
https://www.evaluate.com/vantage/articles/news/snippets/jjs-short-sharp-covid-19-hit-could-still-prove-best-case
https://www.wsj.com/articles/johnson-johnsons-profit-rises-on-higher-consumer-products-sales-11586862436

JNJ lowered 2020 non-GAAP EPS guidance to $7.50-7.90 (from the prior range of $8.95-9.10).

The stock is +4% today, partly on the announced dividend increase (https://finance.yahoo.com/news/johnson-johnson-announces-dividend-increase-103000641.html ).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now